Stocks are near their most expensive level since the dot-com bubble of 2000. The S&P 500 Index is trading at more than 21 times projected earnings in the next year, well above its 10-year average. These outsized gains have fanned worries of a bubble. Rivian, which has yet to generate revenue, more than doubled in its first few sessions, briefly surpassing Volkswagen AG in market value, while Korea’s SK Bioscience Co. “We are moving from a perfect market for IPOs with plenty of liquidity and deals performing well to a more normal environment,” where investors are more selective, said Gareth McCartney, global co-head of equity capital markets at UBS Group AG.Ī retail-buying frenzy that sent stock markets on a rollercoaster ride this year, along with investor appetite for hot sectors has fueled some dizzying post-listing pops. and casting a shadow over Hong Kong’s IPO market. China’s crackdown on technology companies over the summer sent shockwaves through global markets, halting the record rush of Chinese listings in the U.S. Regulatory scrutiny has cooled the SPAC craze, which reached a fever pitch early this year. Still, it hasn’t all been smooth sailing. And the economic recovery from the pandemic along with stimulus measures helped boost corporate earnings.
These companies took advantage of record-high stock prices, as central bank support kept investors flush with cash. Asia’s biggest was China Telecom Corp.’s 54 billion-yuan ($8.4 billion) IPO in August, while Polish parcel-locker provider InPost SA seized the top spot in Europe with its 2.8 billion-euro ($3.2 billion) Amsterdam listing in January. Also highlighted will be recently presented positive clinical data for Xoft® Brain IORT as viable treatment option for glioblastoma multiforme.Leading the pack is electric-truck startup Rivian Automotive Inc., which raised nearly $12 billion in New York this month. iCAD Technology Innovation Day – Expanded Therapy Portfolioįeaturing presentations by Key Opinion Leaders (KOLs) Janie Grumley, MD, FACS (John Wayne Cancer Center), Té Vuong, MD, FRCP (McGill University & Jewish General Hospital), and Santosh Kesari, MD, PhD (John Wayne Cancer Center), who discuss the current treatment landscape and unmet medical need in treating patients with cancers such as breast, rectal, and glioblastoma multiforme. Conant, MD (University of Pennsylvania Perelman School of Medicine) who will discuss the current landscape for digital breast tomosynthesis (DBT) and the potential for iCAD's recently introduced ProFound AI Risk, the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation based solely on a screening mammogram. Nepute, MD (Indiana University Health-Arnett), and Emily F. iCAD Technology Innovation Day – Expanded ProFound AI Portfolioįeaturing presentations by Key Opinion Leaders Per Hall, MD, PhD (Karolinska Institutet), Axel Gräwingholt, MD (Radiologie am Theater), Joshua A. Learn how the latest technology can help clinicians optimize workflow and patient care during the COVID-19 recovery period and beyond. During this virtual event, leading experts from the breast care community shared insights about new innovations in imaging and risk-assessment that may help the clinical community address emerging pandemic challenges, and best practices for how facilities can recuperate from the impact of COVID-19. Pandemic Recovery: How New Technology Can Support Clinicians and Patients in the Aftermath of COVID-19Īs we shift from the peak of the pandemic to recovery mode, clinicians are in need of new solutions to navigate today’s challenges.
#Icad events skin#
Smith, MD, Dermatologist, Chief Executive Officer, Georgia Skin & Cancer Clinic Matt Dewey, Chief Information Officer, Wake Radiology.Meghan Musser, DO, Radiologist, Kettering Health.Sally Grady, Director, Kettering Breast Evaluation Centers, Kettering Health.Angela Fried, MD, Director of Breast Imaging, SimonMed Imaging.Learn how iCAD’s portfolio of deep-learning AI breast health solutions and the Xoft System offer practical solutions that are expertly engineered to enhance clinical workflow, optimize operational efficiency, and improve outcomes for patients. Watch iCAD’s 2nd annual virtual investor webinar, featuring leading clinical and administrative experts who will share unique perspectives on iCAD’s innovative cancer detection and treatment technologies. Optimizing outcomes and efficiency: iCAD’s world-class solutions for the early detection and treatment of cancer
0 kommentar(er)
